1. STAT5B leukemic mutations, altering SH2 tyrosine 665, have opposing impacts on immune gene programs.
- Author
-
Lee HK, Chen J, Philips RL, Lee SG, Feng X, Wu Z, Liu C, Schultz AB, Dalzell M, Birnbaum F, Sexton JA, Keating AE, O'Shea JJ, Young NS, Villarino AV, Furth PA, and Hennighausen L
- Abstract
STAT5B is a vital transcription factor for lymphocytes. Here, function of two STAT5B mutations from human T cell leukemias: one substituting tyrosine 665 with phenylalanine (STAT5B
Y665F ), the other with histidine (STAT5BY665H ) was interrogated. In silico modeling predicted divergent energetic effects on homodimerization with a range of pathogenicity. In primary T cells in vitro STAT5BY665F showed gain-of-function while STAT5BY665H demonstrated loss-of-function. Introducing the mutation into the mouse genome illustrated that the gain-of-function Stat5bY665F mutation resulted in accumulation of CD8+ effector and memory and CD4+ regulatory T-cells, altering CD8+ /CD4+ ratios. In contrast, STAT5BY665H 'knock-in' mice showed diminished CD8+ effector and memory and CD4+ regulatory T cells. In contrast to wild-type STAT5, the STAT5BY665F variant displayed greater STAT5 phosphorylation, DNA binding and transcriptional activity following cytokine activation while the STAT5BY665H variant resembled a null. The work exemplifies how joining in silico and in vivo studies of single nucleotides deepens our understanding of disease-associated variants, revealing structural determinants of altered function, defining mechanistic roles, and, specifically here, identifying a gain-of function variant that does not directly induce hematopoietic malignancy.- Published
- 2024
- Full Text
- View/download PDF